Table 1 Characterization of the main effects of CCND1 and COMT polymorphisms in Ontario and Finland cases.
From: Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
| Â | Â | ONTARIO | FINLAND | ||||||
|---|---|---|---|---|---|---|---|---|---|
CCND1 Activity | Genotype | Controls N (%) | Cases N (%) | OR | 95% CI | Controls N (%) | Cases N (%) | OR | 95% CI |
CCND1Low | GG | 217 (30.2) | 335 (27.4) | 1 | - | 195 (29) | 179 (25.1) | 1 | - |
CCND1Medium | AG | 346 (48.1) | 573 (46.9) | 1.1 | 0.86–1.33 | 334 (49.7) | 355 (49.8) | 1.2 | 0.9–1.49 |
CCND1High | AA | 156 (21.7) | 314 (25.7) | 1.3 | 1.01–1.69 | 143 (21.3) | 179 (25.1) | 1.4 | 1.01–1.84 |
CCND1Medium/CCND1High | AG/AA | 502 (69.8) | 887 (72.6) | 1.15 | 0.93–1.4 | 477 (71) | 534 (74.9) | 1.22 | 0.96–1.55 |
Total | 719 | 1222 | Â | Â | 672 | 713 | Â | Â | |
| Â | Â | ONTARIO | FINLAND | ||||||
COMT Activity | Genotype | Controls N (%) | Cases N (%) | OR | 95% CI | Controls N (%) | Cases N (%) | OR | 95% CI |
COMTLow | AA (MetMet) | 201 (28.2) | 273 (22.4) | 1 | - | 168 (30.60) | 206 (29.10) | 1 | - |
COMTMedium | AG (MetVal) | 353 (49.5) | 642 (52.8) | 1.3 | 1.07–1.68 | 267 (48.63) | 361 (50.99) | 1.1 | 0.85–1.43 |
COMTHigh | GG (Val) | 160 (22.4) | 302 (24.8) | 1.4 | 1.07–1.81 | 114 (20.77) | 141 (19.92) | 1 | 0.73–1.39 |
COMTMedium/COMTHigh | AG (MetVal)/GG(ValVal) | 513 (71.9) | 944 (77.6) | 1.36 | 1.1–1.67 | 381 (69.4) | 502 (70.91) | 1.1 | 0.85–1.37 |
Total | 714 | 1217 | Â | Â | 549 | 708 | Â | Â | |